migalastat
Sign in to saveMigalastat, sold under the brand name Galafold, is a medication used for the treatment of Fabry disease, a rare genetic disorder. Migalastat is an alpha-galactosidase A (alpha-Gal A) pharmacological chaperone. It was developed by Amicus Therapeutics.
Key facts
- Drug.image
- 1-Deoxygalactonojirimycin.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 125
- Drug.pronounce
- mi GAL a stat
- Drug.tradename
- Galafold
- Drug.MedlinePlus
- a625101
- Drug.DailyMedID
- Migalastat
- Drug.pregnancy_AU
- B3
- Drug.routes_of_administration
- By mouth
- Drug.class
- Pharmacological chaperone
- Drug.ATC_prefix
- A16
- Drug.ATC_suffix
- AX14
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.legal_status
- JP: Rx-only
- Drug.bioavailability
- 75%
via Wikipedia infobox
Article
11 sectionsContents
- Medical uses
- Adverse effects
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- Chemistry
- History
- Society and culture
- Legal status
- References
Migalastat, sold under the brand name Galafold, is a medication used for the treatment of Fabry disease, a rare genetic disorder. Migalastat is an alpha-galactosidase A (alpha-Gal A) pharmacological chaperone. It was developed by Amicus Therapeutics.
The most common adverse drug reactions include headache, nasal and throat irritation (nasopharyngitis), urinary tract infection, nausea, and fever (pyrexia).